Financial Statements · From SEC 10-K & 10-Q XBRL Filings
West Pharmaceutical Services Inc. Revenue & Financial Statements
West Pharmaceutical Services Inc. reported revenue of $3.1B for the fiscal year ended December 31, 2025, up 6.3% year over year, with net income of $493.7M and diluted EPS of $6.79.
- Company
- West Pharmaceutical Services Inc. WST · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 2.8B | 2.9B | 2.9B | 2.9B | 3.1B |
| Cost of revenue | 1.7B | 1.8B | 1.8B | 1.9B | 2.0B |
| Gross profit | 1.2B | 1.1B | 1.1B | 998.5M | 1.1B |
| Operating income | 752.3M | 734.0M | 676.0M | 569.9M | 584.9M |
| Pretax income | 420.0M | 394.4M | 369.4M | 243.4M | 372.6M |
| Net income | 661.8M | 585.9M | 593.4M | 492.7M | 493.7M |
| Diluted EPS | 8.67 | 7.73 | 7.88 | 6.69 | 6.79 |
| EBITDA | 869.2M | 850.9M | 809.7M | 721.7M | 756.3M |
Quarterly
| USD | Q4 '24 | Q2 '25 | Q1 '25 | Q3 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 748.8M | — | 698.0M | — | 766.5M | 804.6M | 805.0M | 844.9M |
| Cost of revenue | 475.2M | — | 466.1M | — | 492.6M | 510.3M | 501.1M | 548.5M |
| Gross profit | 273.6M | — | 231.9M | — | 273.9M | 294.3M | 303.9M | 296.4M |
| Operating income | 159.6M | — | 107.0M | — | 153.7M | 167.6M | 156.6M | 177.1M |
| Pretax income | 164.9M | — | 110.5M | — | 157.0M | 171.9M | 161.5M | 180.1M |
| Net income | 130.1M | 89.8M | 89.8M | 131.8M | 131.8M | 140.0M | 132.1M | 138.8M |
| Diluted EPS | 1.78 | — | 1.23 | — | 1.82 | 1.92 | 1.82 | 1.92 |
| EBITDA | 199.4M | — | 146.1M | — | 195.1M | 209.9M | 203.6M | 222.3M |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 3.3B | 3.6B | 3.8B | 3.6B | 4.3B |
| Current assets | 1.7B | 1.9B | 1.9B | 1.5B | 2.0B |
| Cash & equivalents | 762.6M | 894.3M | 853.9M | 484.6M | 791.3M |
| Total liabilities | 978.4M | 931.9M | 948.5M | 961.1M | 1.1B |
| Current liabilities | 594.1M | 519.0M | 671.8M | 550.4M | 654.9M |
| Long-term debt | 208.8M | 206.7M | 72.8M | 202.6M | 202.8M |
| Total debt | 253.0M | 208.9M | 206.8M | 202.6M | 202.8M |
| Stockholders’ equity | 2.3B | 2.7B | 2.9B | 2.7B | 3.2B |
| Net debt | (509.6M) | (685.4M) | (647.1M) | (282.0M) | (588.5M) |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 584.0M | 724.0M | 776.5M | 653.4M | 754.8M |
| Investing cash flow | (253.1M) | (288.2M) | (368.7M) | (378.7M) | (285.9M) |
| Financing cash flow | (168.1M) | (293.6M) | (459.6M) | (622.6M) | (185.1M) |
| Capital expenditure | 253.4M | 284.6M | 362.0M | 377.0M | 285.9M |
| Free cash flow | 330.6M | 439.4M | 414.5M | 276.4M | 468.9M |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 37.5M | 23.7M | 23.3M | 18.7M | 23.8M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every WST filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.